REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the appointment of Matt Wiley as Chief Commercial Officer. In this newly created position, Matt will be responsible for the development and execution of commercial strategies of the company’s product portfolio, including the planned launches of FMX101 for acne and FMX103 for rosacea.
“Matt has an exceptional commercial record in pharmaceuticals and brings valuable experience and depth of knowledge in marketing, market access, and product launches,” said David Domzalski, Chief Executive Officer of Foamix. “He will be a key addition to the Foamix team as we pursue regulatory filings for our lead candidates FMX101 for acne and FMX103 for rosacea and prepare to launch these products. We look forward to benefitting from his experience and insights as we transition to becoming a fully integrated, commercial stage company.”
Matt Wiley joins Foamix with more than 20 years of commercial experience across a broad range of specialty pharmaceutical categories. Prior to joining Foamix, Mr. Wiley spent six years at Jazz Pharmaceuticals. Most recently he was Vice President of Marketing and Business Unit Lead for the company’s sleep disorder portfolio. During this period, he led the efforts to unlock additional value of the company’s largest business unit, including Jazz Pharmaceuticals’ most successful product, Xyrem®, which grew fivefold to over $1 billion in annual sales. Prior to Jazz, Mr. Wiley was Vice President of Marketing at Azur Pharma where he was responsible for all brand management across the company’s women’s health and CNS businesses before the company was acquired by Jazz in 2012. Earlier in his career, he held roles of increasing responsibility in sales, marketing, and training at Guilford/MGI Pharma, Salix, Cephalon, and Rhone-Poulenc Rorer. He holds a bachelor’s degree in English from Syracuse University.
“Joining Foamix is a tremendous opportunity,” said Matt Wiley, newly appointed Chief Commercial Officer of Foamix. “I am enthusiastic about the commercial prospects for both FMX101 and FMX103 and their potential to address serious unmet needs in acne and rosacea. I look forward to leading the efforts to bring these products to market and contributing to Foamix’s success.”
About Foamix Pharmaceuticals
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our leading clinical stage product candidates are FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne and FMX103, our novel minocycline foam for the treatment of rosacea. We continue to pursue research & development of our proprietary, innovative foam technologies for the treatment of various skin conditions. We currently have development and license agreements relating to our technology with various pharmaceutical companies including LEO Pharma A/S and others.
Foamix uses its website (www.Foamix.com) as a channel to distribute information about Foamix and its product candidates from time to time. Foamix may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Foamix’s website in addition to following its press releases, filings with the Securities & Exchange Commission, public conference calls, and webcasts.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions created by those sections. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions, expectations, forecasts, beliefs or intentions related to financial results, commercial results, timing and results of clinical trials and U.S. FDA and other regulatory agencies authorizations. Forward-looking statements are based on our current knowledge and our present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors including, but not limited to, unexpected delays in clinical trials or announcement of results, excess costs or unfavorable results of clinical trials, delays or denial in the U.S. FDA approval process, additional competition in the acne and dermatology markets, denial of reimbursement by third party payors or inability to raise additional capital, our ability to recruit and retain key employees and our ability to stay in compliance with applicable laws, rules and regulations. We discuss many of these risks in greater detail in our annual and other periodic filings with the SEC, including under the heading “Risk Factors” in our most recent annual report. Although we believe these forward-looking statements are reasonable, they speak only as of the date of this announcement and Foamix undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.
Ilan Hadar, CFO & Country Manager
Foamix Pharmaceuticals Ltd.
|U.S. Investor Relations |
LifeSci Advisors, LLC
Elizabeth Tang, PhD
LifeSci Public Relations